0

Pharmacokinetics and Bioequivalence Study of Doxycycline Capsules in Healthy Male Subjects

Michael H Gschwend, Wolfgang Martin, Aydin Erenmemişoğlu, Margit Scherm, Carmen Dilger, Uygur Tamur, Ilker Kanzik, A Atilla Hincal

Arzneimittelforschung. 2007;57(6):347-51.

PMID: 17688080

Abstract:

The aim of the present study was to compare the bioavailability of doxycycline (CAS 564-25-0) from two different doxycycline hyclate (CAS 24390-14-5) capsules (Monodoks 100 mg capsule as test preparation and 100 mg capsule of the originator product as reference preparation) in 24 healthy male subjects. The study was conducted according to an open-label, randomised two-period cross-over design with a wash-out phase of 16 days. Blood samples for pharmacokinetic profiling were taken up to 72 h post-dose, and doxycycline plasma concentrations were determined with a validated HPLC method with UV-detection. Maximum plasma concentrations (Cmax) of 1,715.1 ng/ml (test) and 1,613.3 ng/ml (reference) were achieved. Areas under the plasma concentration-time curve (AUC(0-infinity)) of 28,586.5 ng x h/ml (test) and 29,047.5 ng x h/ml (reference) were calculated. The median tmax was 1.88 h (test) and 2.00 h (reference). Plasma elimination half-lives (t1/2) of 16.49 h (test) and 16.75 h (reference) were determined. Both primary target parameters AUC(0-infinity) and Cmax were tested parametrically by analysis of variance (ANOVA) and the 92.39 %-103.53% (AUC(0-infinity)) and 98.45%-111.74% (Cmax). Bioequivalence between test and reference preparation was demonstrated since for both parameters AUC and Cmax the 90% confidence intervals of the T/R ratios of logarithmically transformed data were in the generally accepted range of 80 0%-125%.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP24390145-A Doxycycline, Hyclate - CAS 24390-14-5 Doxycycline, Hyclate - CAS 24390-14-5 24390-14-5 Price
qrcode